商品编号


AG-40T-0102-C050



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

50 ?g


商品信息


More Information



Product Details



Synonyms

hKAT II; KAT2; α-Amino
ADI
pate Aminotransferase (Mitochondrial); AADAT; EC 2.6.1.7



Product Type

Protein



Properties



Source/Host

E. coli



Sequence

Human full-length KAT II is fused at the N-terminus to a His-tag.



Crossreactivity

Human



Application

Can be used to test potential kynurenic acid synthesis inhibitors by performing either
in vitro
end point assays followed by HPLC-UV (Lit. 2) or continuous spectrophotometric analysis (Lit. 3).



MW

~49.8kDa



Purity

≥97% (SDS-PAGE)



Endotoxin Content

N/A



Concentration

0.5mg/ml (Lot specific)



Formulation

Liquid. In 50 mM phosphate buffer pH 8.0, containing 50mM sodium chloride and 40μM pyridoxal 5'-phosphate (PLP).



Other Product Data

NCBI link NP_872603: AADAT (human)



Shipping and Handling



Shipping

DRY ICE



Short Term Storage

-20°C



Long Term Storage

-80°C



Handling Advice

After opening, prepare aliquots and store at -80°C.
Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 6 months after receipt when stored at -80°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF





Kynurenine aminotransferases (KATs) are pyridoxal-5’-phosphate-dependent enzymes that catalyze the conversion of L-kynurenine into kynurenic acid, a neuroactive metabolite whose unbalancing is associated with a number of brain disorders. Biochemical and structural investigations revealed that L-kynurenine (L-KYN) recognition by hKAT II is achieved by exploiting structural features that are peculiar of this isoform, thus offering the possibility to select/design inhibitor molecules specifically targeting hKAT II to be used as modulators of kynurenic acid synthesis in the CNS. hKAT II is one of the aminotransferases involved in the pyridoxal 5'-phosphate (PLP)-dependent irrevers
IBL
e transamination of L-kynurenine (L-KYN) to kynurenic acid (KYNA) in the central nervous system. When assayed
in vitro
the protein also displays β-elimination activity.


Product References

Crystal Structure of Human Kynurenine Aminotransferase II, a Drug Target for the Treatment of Schizophrenia; F. Rossi, et al.; J. Biol. Chem.
283
, 3559 (2008)

Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?; V. Casazza, et al.; Curr. Top. Med. Chem.
11
, 148 (2011)

Human kynurenine aminotransferase II - reactivity with substrates and inhibitors; E. Passera, et al.; FEBS J.
278
, 1882 (2011)